Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer.
Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer.
复制标题
DOI：
10.2147/dddt.s112113
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Cekanova M
中科院分区：
文献类型：
--
作者：
Smolensky D;Rathore K;Cekanova M
膀胱癌仍然是在美国治疗的最昂贵的癌症之一，由于所需的治疗时间和复发程度。为了更有效地治疗膀胱癌，正在研究靶向治疗。为了在患者中使用靶向治疗，重要的是提供患者的遗传背景。基因组测序以及转录组分析的最新进展已经确定了膀胱癌中改变的主要途径组分。本文综述了膀胱癌的病因、诊断、分期、治疗、动物模型以及信号通路等方面的研究进展。主要关注PI 3 K/AKT通路，p53/pRb信号通路和组蛋白修饰机制。由于在膀胱癌的治疗中也出现了几种有前途的免疫疗法，因此还关注免疫系统的一般激活以治疗膀胱癌。
Bladder cancer remains one of the most expensive cancers to treat in the United States due to the length of required treatment and degree of recurrence. In order to treat bladder cancer more effectively, targeted therapies are being investigated. In order to use targeted therapy in a patient, it is important to provide a genetic background of the patient. Recent advances in genome sequencing, as well as transcriptome analysis, have identified major pathway components altered in bladder cancer. The purpose of this review is to provide a broad background on bladder cancer, including its causes, diagnosis, stages, treatments, animal models, as well as signaling pathways in bladder cancer. The major focus is given to the PI3K/AKT pathway, p53/pRb signaling pathways, and the histone modification machinery. Because several promising immunological therapies are also emerging in the treatment of bladder cancer, focus is also given on general activation of the immune system for the treatment of bladder cancer.
BFGF基因表达和肾上腺髓质细胞中BFGF蛋白的亚细胞分布的调节。
影响因子：
7.8
作者：
Stachowiak, M K;Moffett, J;Joy, A;Puchacz, E;Florkiewicz, R;Stachowiak, E K
通讯作者：
Stachowiak, E K